906 related articles for article (PubMed ID: 33068703)
1. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
Front Immunol; 2020; 11():573526. PubMed ID: 33162987
[TBL] [Abstract][Full Text] [Related]
4. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
5. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
[TBL] [Abstract][Full Text] [Related]
6. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
Xie X; Muruato AE; Zhang X; Lokugamage KG; Fontes-Garfias CR; Zou J; Liu J; Ren P; Balakrishnan M; Cihlar T; Tseng CK; Makino S; Menachery VD; Bilello JP; Shi PY
Nat Commun; 2020 Oct; 11(1):5214. PubMed ID: 33060595
[TBL] [Abstract][Full Text] [Related]
7. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
Amanat F; White KM; Miorin L; Strohmeier S; McMahon M; Meade P; Liu WC; Albrecht RA; Simon V; Martinez-Sobrido L; Moran T; García-Sastre A; Krammer F
Curr Protoc Microbiol; 2020 Sep; 58(1):e108. PubMed ID: 32585083
[TBL] [Abstract][Full Text] [Related]
8. A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells.
Hasler F; Duda A; Kündig TM; Johansen P
STAR Protoc; 2021 Dec; 2(4):100824. PubMed ID: 34467223
[TBL] [Abstract][Full Text] [Related]
9. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
[TBL] [Abstract][Full Text] [Related]
11. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Valcourt EJ; Manguiat K; Robinson A; Chen JC; Dimitrova K; Philipson C; Lamoureux L; McLachlan E; Schiffman Z; Drebot MA; Wood H
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115294. PubMed ID: 33387896
[TBL] [Abstract][Full Text] [Related]
13. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
[TBL] [Abstract][Full Text] [Related]
14. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
Vandergaast R; Carey T; Reiter S; Lathrum C; Lech P; Gnanadurai C; Haselton M; Buehler J; Narjari R; Schnebeck L; Roesler A; Sevola K; Suksanpaisan L; Bexon A; Naik S; Brunton B; Weaver SC; Rafael G; Tran S; Baum A; Kyratsous CA; Peng KW; Russell SJ
mSphere; 2021 Jun; 6(3):e0017021. PubMed ID: 34077262
[TBL] [Abstract][Full Text] [Related]
15. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
17. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect
Amanat F; Strohmeier S; Lee WH; Bangaru S; Ward AB; Coughlan L; Krammer F
mBio; 2021 Aug; 12(4):e0100221. PubMed ID: 34311574
[TBL] [Abstract][Full Text] [Related]
18. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays.
Bewley KR; Coombes NS; Gagnon L; McInroy L; Baker N; Shaik I; St-Jean JR; St-Amant N; Buttigieg KR; Humphries HE; Godwin KJ; Brunt E; Allen L; Leung S; Brown PJ; Penn EJ; Thomas K; Kulnis G; Hallis B; Carroll M; Funnell S; Charlton S
Nat Protoc; 2021 Jun; 16(6):3114-3140. PubMed ID: 33893470
[TBL] [Abstract][Full Text] [Related]
19. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
Viruses; 2021 May; 13(5):. PubMed ID: 34065987
[TBL] [Abstract][Full Text] [Related]
20. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
